Mississippi 340B law upheld by appeals court in two cases
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin enforcement of the state’s law protecting 340B pricing for contract pharmacy arrangements. The 5th Circuit rejected a similar challenge by AbbVie in September 2025. The AHA filed an amicus brief in defense of Mississippi’s 340B contract pharmacy law in June 2024.
Related News Articles
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The AHA May 27 filed an amicus brief in the 7th U.S. Circuit Court of Appeals supporting the dismissal of an online tracking lawsuit against a member hospital…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The White House May 18 announced an expansion of TrumpRx.gov, which now features more than 600 generic drugs. The direct-to-consumer platform serves as a hub…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…